Entrada Therapeutics Inc. (TRDA)
Entrada Therapeutics Statistics
Share Statistics
Entrada Therapeutics has 37.59M shares outstanding. The number of shares has increased by 1.26% in one year.
| Shares Outstanding | 37.59M |
| Shares Change (YoY) | 1.26% |
| Shares Change (QoQ) | 0.47% |
| Owned by Institutions (%) | 75.32% |
| Shares Floating | 22M |
| Failed to Deliver (FTD) Shares | 34 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 1.17M, so 3.1% of the outstanding shares have been sold short.
| Short Interest | 1.17M |
| Short % of Shares Out | 3.1% |
| Short % of Float | 4.95% |
| Short Ratio (days to cover) | 12.09 |
Valuation Ratios
The PE ratio is 9.83 and the forward PE ratio is -2.65. Entrada Therapeutics's PEG ratio is -0.01.
| PE Ratio | 9.83 |
| Forward PE | -2.65 |
| PS Ratio | 3.06 |
| Forward PS | 0.7 |
| PB Ratio | 1.5 |
| P/FCF Ratio | -14.43 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Entrada Therapeutics has an Enterprise Value (EV) of 603.02M.
| EV / Sales | 2.86 |
| EV / EBITDA | 12.83 |
| EV / EBIT | -14.51 |
| EV / FCF | -13.49 |
Financial Position
The company has a current ratio of 11.15, with a Debt / Equity ratio of 0.14.
| Current Ratio | 11.15 |
| Quick Ratio | 11.15 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 1.26 |
| Debt / FCF | -1.32 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 15.31% and Return on Invested Capital is 9.39%.
| Return on Equity | 15.31% |
| Return on Assets | 12.47% |
| Return on Invested Capital | 9.39% |
| Revenue Per Employee | $1.15M |
| Profits Per Employee | $358.61K |
| Employee Count | 183 |
| Asset Turnover | 0.4 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 859K |
| Effective Tax Rate | 1.29% |
Stock Price Statistics
The stock price has increased by -29.93% in the last 52 weeks. The beta is 0.03, so Entrada Therapeutics's price volatility has been higher than the market average.
| Beta | 0.03 |
| 52-Week Price Change | -29.93% |
| 50-Day Moving Average | 10.3 |
| 200-Day Moving Average | 14.95 |
| Relative Strength Index (RSI) | 46 |
| Average Volume (20 Days) | 132.9K |
Income Statement
In the last 12 months, Entrada Therapeutics had revenue of 210.78M and earned 65.63M in profits. Earnings per share was 1.76.
| Revenue | 210.78M |
| Gross Profit | 210.78M |
| Operating Income | 47.01M |
| Net Income | 65.63M |
| EBITDA | 47.01M |
| EBIT | 47.01M |
| Earnings Per Share (EPS) | 1.76 |
Balance Sheet
The company has 101.21M in cash and 59.21M in debt, giving a net cash position of 42M.
| Cash & Cash Equivalents | 101.21M |
| Total Debt | 59.21M |
| Net Cash | 42M |
| Retained Earnings | -129.34M |
| Total Assets | 526.32M |
| Working Capital | 400.56M |
Cash Flow
In the last 12 months, operating cash flow was -41.56M and capital expenditures -3.16M, giving a free cash flow of -44.72M.
| Operating Cash Flow | -41.56M |
| Capital Expenditures | -3.16M |
| Free Cash Flow | -44.72M |
| FCF Per Share | -1.2 |
Margins
Gross margin is 100%, with operating and profit margins of 22.3% and 31.13%.
| Gross Margin | 100% |
| Operating Margin | 22.3% |
| Pretax Margin | 31.54% |
| Profit Margin | 31.13% |
| EBITDA Margin | 22.3% |
| EBIT Margin | 22.3% |
| FCF Margin | -21.21% |
Dividends & Yields
TRDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 10.17% |
| FCF Yield | -6.93% |
Analyst Forecast
The average price target for TRDA is $28, which is 221.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 221.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 3.21 |
| Piotroski F-Score | 5 |